long intergenic non-protein coding RNA 1238Genealiases: []
Q-omics provides the consensus-scored LINC01238 profile across patient tissues and cancer cell-line models. LINC01238 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01238 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, LINC01238 RNA expression shows 18,471 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where LINC01238 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01238 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01238 survival associations across molecular data types. LINC01238 RNA expression shows survival associations in the most cancer types (25). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01238 RNA expression–survival associations across cancer types. High LINC01238 expression shows unfavorable associations in KIRC and UVM, but favorable associations in HNSC, SKCM, READ and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01238 RNA expression.
This table summarizes LINC01238 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01238. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01238 shows lower tumor expression in THCA, KICH and BLCA and higher tumor expression in KIRC, BRCA and STAD. The KIRC box plot shows higher LINC01238 RNA expression in tumor versus normal tissue (log2 FC = +0.182, t-test p < 0.001).
This table shows molecular features associated with LINC01238 in patient tissues and cancer cell lines. In patient samples, LINC01238 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
